JPH0113688B2 - - Google Patents
Info
- Publication number
- JPH0113688B2 JPH0113688B2 JP18934982A JP18934982A JPH0113688B2 JP H0113688 B2 JPH0113688 B2 JP H0113688B2 JP 18934982 A JP18934982 A JP 18934982A JP 18934982 A JP18934982 A JP 18934982A JP H0113688 B2 JPH0113688 B2 JP H0113688B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- day
- sorafur
- flamag
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 32
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 8
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 5
- 239000001095 magnesium carbonate Substances 0.000 claims description 5
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 21
- 229940079593 drug Drugs 0.000 description 16
- 239000003242 anti bacterial agent Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 229960000564 nitrofurantoin Drugs 0.000 description 11
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 10
- 230000003385 bacteriostatic effect Effects 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 229960002375 furazidin Drugs 0.000 description 6
- DECBQELQORZLLP-UAIOPKHMSA-N 1-[(e)-[(e)-3-(5-nitrofuran-2-yl)prop-2-enylidene]amino]imidazolidine-2,4-dione Chemical compound O1C([N+](=O)[O-])=CC=C1\C=C\C=N\N1C(=O)NC(=O)C1 DECBQELQORZLLP-UAIOPKHMSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical class NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 231100001231 less toxic Toxicity 0.000 description 4
- 229960001907 nitrofurazone Drugs 0.000 description 4
- 206010034674 peritonitis Diseases 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 208000014001 urinary system disease Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 2
- 208000008081 Intestinal Fistula Diseases 0.000 description 2
- 208000032376 Lung infection Diseases 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 229940124575 antispasmodic agent Drugs 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- 238000002192 cholecystectomy Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000036325 urinary excretion Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- KVYKDNGUEZRPGJ-UHFFFAOYSA-N 1-Aminohydantoin Chemical compound NN1CC(=O)NC1=O KVYKDNGUEZRPGJ-UHFFFAOYSA-N 0.000 description 1
- NXFQHRVNIOXGAQ-UHFFFAOYSA-N 1-[(5-nitro-2-furanyl)methylideneamino]imidazolidine-2,4-dione Chemical group O1C([N+](=O)[O-])=CC=C1C=NN1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-UHFFFAOYSA-N 0.000 description 1
- 208000000197 Acute Cholecystitis Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000194106 Bacillus mycoides Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010008614 Cholecystitis acute Diseases 0.000 description 1
- 206010062631 Cholecystitis infective Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010061822 Drug intolerance Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QECVIPBZOPUTRD-UHFFFAOYSA-N N=S(=O)=O Chemical class N=S(=O)=O QECVIPBZOPUTRD-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000000407 Pancreatic Cyst Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- ZKIAXFGFUSGPGQ-NGTWICJZSA-M potassium;3-[(e)-[(e)-3-(5-nitrofuran-2-yl)prop-2-enylidene]amino]-5-oxo-4h-imidazol-2-olate Chemical compound [K+].[O-]C1=NC(=O)CN1\N=C\C=C\C1=CC=C([N+]([O-])=O)O1 ZKIAXFGFUSGPGQ-NGTWICJZSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18934982A JPS5982314A (ja) | 1982-10-29 | 1982-10-29 | 抗菌性医薬組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18934982A JPS5982314A (ja) | 1982-10-29 | 1982-10-29 | 抗菌性医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5982314A JPS5982314A (ja) | 1984-05-12 |
| JPH0113688B2 true JPH0113688B2 (enExample) | 1989-03-07 |
Family
ID=16239837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18934982A Granted JPS5982314A (ja) | 1982-10-29 | 1982-10-29 | 抗菌性医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5982314A (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898729A (en) * | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
| JPH0621962U (ja) * | 1992-07-23 | 1994-03-22 | 昌一 柴田 | 紙めくり用タツクシール |
-
1982
- 1982-10-29 JP JP18934982A patent/JPS5982314A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5982314A (ja) | 1984-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2755550B2 (ja) | ヘリコバクター・ピロリに起因する胃性消化不良を治療するためのリファキシミンを含有する医薬製剤 | |
| Guay | An update on the role of nitrofurans in the management of urinary tract infections | |
| Gary et al. | Gentamicin-associated acute renal failure | |
| Kunin et al. | Persistence of antibiotics in blood of patients with acute renal failure. I. Tetracycline and chlortetracycline | |
| JP5409710B2 (ja) | 心肺バイパス（ｃｐｂ）手術の術後合併症を低減するための組成物 | |
| JPS6064918A (ja) | 消炎剤注射液 | |
| JPS6248623A (ja) | 胃腸疾患の治療のための医薬組成物 | |
| Kunin | Nephrotoxicity of antibiotics | |
| JPS60105617A (ja) | 骨炎及び骨髄炎予防治療組成物 | |
| Barillo | Topical antimicrobials in burn wound care: a recent history | |
| JPH0113688B2 (enExample) | ||
| US4500516A (en) | Antibacterial pharmaceutical composition | |
| JPS62161726A (ja) | 胃腸障害の治療及び予防のためのニトロフラントインの使用 | |
| US7811609B2 (en) | Use of metal compounds to treat gastrointestinal infections | |
| Munoz et al. | Arterial hypertension in infants with hydronephrosis: Report of six cases | |
| Fabre et al. | The behaviour in man of CP 15,464, a carbenicillin absorbed following oral administration | |
| WO1997009988A1 (en) | A biologically active preparation containing vinylene ethonium and decamethoxin | |
| RU2157384C2 (ru) | Комплекс 1-(2-гидроксиэтил)-2-метил-5-нитроимидазола с поливинилпирролидоном, способ его получения и фармацевтическая композиция, обладающая антимикробным действием | |
| Rinkoff et al. | Toxic depression of the myeloid elements following therapy with the sulfonamides; report of 8 cases | |
| Necheles et al. | Peptic Ulcer in Man Part 4. A New Antacid Made To Meet Requirements Of Antacid Therapy, Chemical And Laboratory Work | |
| JPS5938207B2 (ja) | 腎疾患治療剤 | |
| RU2033159C1 (ru) | Способ лечения деструктивного туберкулеза легких | |
| Ito et al. | PREVENTIVE EFFECT OF TAK-751S ON COMPLICATIONS OF HEMORRHAGIC COLITIS RESULTS OF CLINICAL STUDY OF TAK-751S | |
| Romankiewicz | Factors Influencing Renal Distribution of Antibiotics a Key to Therapy of Pyelonephritis | |
| RU2229292C2 (ru) | Фармацевтическая композиция, обладающая противомикробной активностью |